Publication

ISTH •
25 June, 2024 •
•

First Interim Analysis of Clinical Outcomes in Adults and Adolescents With Severe Hemophilia A Receiving Efanesoctocog Alfa Prophylaxis in XTEND-ed, a Phase 3 Long-term Extension Study

Sophie Susen, Stephanie P’ng, Toshko Lissitchkov, Davide Matino, Pratima Chowdary, Angela Weyand, Robert Klamroth, Young-Shil Park, María Teresa Álvarez Román, Liqi Feng, Helena Palmborg, Jennifer Dumont , Elena Santagostino, Lila-Sabrina Fetita, Keiji Nogami

Available materials

Oral Presentation

Publication

ISTH •
25 June, 2024 •
•

Long-term Outcomes With Efanesoctocog Alfa Prophylaxis for Previously Treated Children With Severe Hemophilia A, an Interim Analysis of the Phase 3 XTEND-ed Study

Lynn Malec, Beatrice Nolan, Anthony KC Chan, Manuela Albisetti, Sheng-Chieh Chou, Bulent Zulfikar, Mindy Simpson, Liqi Feng, Helena Palmborg, Graham Neill, Lydia Abad-Franch, Sriya Gunawardena, Karin Fijnvandraat

Available materials

Oral Presentation

Publication

ISTH •
23 June, 2024 •
•

Perioperative Management with Efanesoctocog Alfa in Adults, Adolescents, and Children with Severe Hemophilia A in the Phase 3 XTEND Clinical Program

Anthony KC Chan, Sophie Susen, Liane Khoo, Annette von Drygalski, Johannes Oldenburg, Ming-Ching Shen, Flora Peyvandi, Cristina Tarango, Pratima Chowdary, Lara Mamikonian, Helena Palmborg, Jennifer Dumont , Elena Santagostino, Cedric Hermans

Available materials

Oral Presentation

Publication

Effectiveness and safety of efmoroctocog alfa (a recombinant factor VIII Fc) across body mass index (BMI) categories: Pooled data from two non-interventional phase 4 studies (A-SURE/PREVENT)

First Interim Analysis of Clinical Outcomes in Adults and Adolescents With Severe Hemophilia A Receiving Efanesoctocog Alfa Prophylaxis in XTEND-ed, a Phase 3 Long-term Extension Study

Long-term Outcomes With Efanesoctocog Alfa Prophylaxis for Previously Treated Children With Severe Hemophilia A, an Interim Analysis of the Phase 3 XTEND-ed Study

Perioperative Management with Efanesoctocog Alfa in Adults, Adolescents, and Children with Severe Hemophilia A in the Phase 3 XTEND Clinical Program

Long-Term Joint Health Outcomes With a Recombinant Factor VIII Fc From the 48-Month Prospective, Observational A-MORE Study: Third Interim Analysis of Up to 24 Months

Joint health outcomes with efanesoctocog alfa in adults/adolescents from XTEND-1 continuing XTEND-ed

Major Surgical Outcomes with Efanesoctocog Alfa: 4 Years’ Experience in the XTEND Clinical Program

Observational Study of Prophylactic Efanesoctocog Alfa for Joint Health in Hemophilia A: PROTECT-ALT

Long-term observational joint health study in patients initiating efanesoctocog alfa: baseline data